LIVE
SNN
Smith & Nephew plc · Healthcare
$29.83
-2.44% this month
VERSUS
⟷
COMPARE
ZBH
Zimmer Biomet Holdings, Inc. · Healthcare
$94.08
+6.22% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
SNN
2
ZBH
2
Comparison scoreboard
MIXED SETUPAI Score
SNN 26.6
ZBH ✓26.8
1Y Return
SNN ✓+1.63%
ZBH +0.31%
Fwd P/E
SNN 13.06
ZBH ✓10.16
Target Up.
SNN ✓+14.24%
ZBH +7.34%
Op. Margin
SNN N/A
ZBH 19.69%
Metrics last refreshed: 7/14/2026
Quick take
SNN vs ZBH: Smith & Nephew vs Zimmer Biomet Stock Comparison: AI Score, Valuation, Performance and Upside
Smith & Nephew and Zimmer Biomet are both mid-sized orthopedic medtech companies competing against Stryker and J&J for joint replacement and robotic surgery market share. Both have underperformed larger peers in recent years; both have robotic surgery platforms facing an uphill battle against Stryker Mako's installed base lead.
SNN vs ZBH is two orthopedic medtech challengers competing to close the gap with Stryker and J&J — Smith & Nephew wins if wound management provides earnings diversification while CORI gains share; Zimmer Biomet wins if ROSA robotic surgery captures meaningful knee replacement market share.
Live analysis · updated 7/14/2026
SNN and ZBH are closely matched — they split the tracked metrics evenly. SNN has delivered stronger 1-year price return (+1.63% vs +0.31%), though ZBH has the better forward P/E setup (10.16x vs 13.06x for SNN). Analyst consensus implies meaningfully more upside for SNN (+14.24%) than for ZBH (+7.34%).
Normalized 1Y performance
SNN
ZBH
Recent returns
SNN
ZBH
Analyst price targets & sentiment
SNN · 5 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.4/5.0)
Price target range
analyst low$30.00
analyst high$38.40
analyst mean$34.07
current price$29.83
+14.2% upside to analyst mean
ZBH · 26 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.6/5.0)
Price target range
analyst low$91.00
analyst high$149.11
analyst mean$98.05
current price$94.08
+7.3% upside to analyst mean
Who should consider this stock?
SNN may suit investors who:
- →want orthopedic medtech exposure diversified across implants, sports medicine, and wound management
- →value Smith & Nephew's wound care segment as a recurring consumable revenue driver
- →prefer a UK-based medtech ADR at a lower valuation than US-listed peers
- →believe CORI robotics can gain traction against Stryker Mako over time
ZBH may suit investors who:
- →prefer US-listed orthopedic medtech focused on knee and hip reconstruction
- →believe ROSA robotic surgery can close the gap with Stryker Mako's installed base
- →value Zimmer Biomet's dental segment as an additional orthopedic-adjacent revenue diversifier
- →are comfortable with operational restructuring risk in exchange for potential margin improvement
Performance & AI score
| Metric | SNN | ZBH |
|---|---|---|
| AI score | 26.6 | 26.8 |
| AI rank | #2580 | #2552 |
| Latest close | $29.83 | $94.08 |
| 1M return | -2.44% | +6.22% |
| 6M return | -10.10% | +1.32% |
| 1Y return | +1.63% | +0.31% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | SNN | ZBH |
|---|---|---|
| 1Y ago | $10.4K (+4.0%) started 2025-07-14 | $10.02K (+0.2%) started 2025-07-14 |
| 5Y ago | $9.19K (-8.1%) started 2021-07-14 | $6.62K (-33.8%) started 2021-07-14 |
| 10Y ago | $13.78K (+37.8%) started 2016-07-14 | $8.83K (-11.7%) started 2016-07-14 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | SNN | ZBH |
|---|---|---|
| Market cap | $12.57B | $17.67B |
| Trailing P/E | 20.86 | 23.66 |
| Forward P/E | 13.06 | 10.16 |
| Price/Sales | 2.04 | 2.37 |
| EV/Revenue | 11.16 | 2.95 |
| Analyst target | $34.07 | $98.05 |
| Target upside | +14.24% | +7.34% |
Growth, profitability & risk
| Metric | SNN | ZBH |
|---|---|---|
| Revenue growth | 7.40% | 9.30% |
| Earnings growth | 70.40% | 34.10% |
| EPS growth | +70.40% | +34.10% |
| FCF margin | +14.22% | +12.42% |
| Operating margin | N/A | 19.69% |
| Profit margin | 10.14% | 9.05% |
| ROIC proxy | 11.84% | 6.07% |
| Return on equity | 11.84% | 6.07% |
| Dividend yield | 2.55% | 1.05% |
| Beta | 0.68 | 0.46 |
| Debt/equity | 62.90 | 59.83 |
| Current ratio | 2.57 | 1.73 |
| Quick ratio | 1.17 | 0.77 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
SNN max drawdown24.01%
ZBH max drawdown26.12%
SNN max wkly drop10.10%
ZBH max wkly drop14.23%
5Y risk snapshot
SNN max drawdown48.63%
ZBH max drawdown48.30%
SNN max wkly drop15.15%
ZBH max wkly drop14.23%
10Y risk snapshot
SNN max drawdown55.06%
ZBH max drawdown52.63%
SNN max wkly drop29.62%
ZBH max wkly drop27.48%
Performance metrics by period
| Period | Metric | SNN | ZBH |
|---|---|---|---|
| 1Y | Growth | +1.63% | +0.23% |
| CAGR | +1.63% | +0.24% | |
| Sharpe ratio | 0.06 | 0.03 | |
| Max drawdown | 24.01% | 26.12% | |
| Max daily drop | 11.72% | 15.15% | |
| Max wkly drop | 10.10% | 14.23% | |
| 5Y | Growth | -20.15% | -35.80% |
| CAGR | -4.40% | -8.49% | |
| Sharpe ratio | -0.19 | -0.36 | |
| Max drawdown | 48.63% | 48.30% | |
| Max daily drop | 13.03% | 15.15% | |
| Max wkly drop | 15.15% | 14.23% | |
| 10Y | Growth | +6.89% | -17.77% |
| CAGR | +0.67% | -1.94% | |
| Sharpe ratio | -0.01 | -0.08 | |
| Max drawdown | 55.06% | 52.63% | |
| Max daily drop | 13.75% | 15.15% | |
| Max wkly drop | 29.62% | 27.48% |
Business comparison
| Category | SNN | ZBH |
|---|---|---|
| Company | Smith & Nephew plc | Zimmer Biomet Holdings, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Medical Devices |
| Core business | Global medtech company with orthopedics (knee, hip implants), sports medicine (arthroscopy), and advanced wound management. Smith & Nephew is headquartered in the UK and trades as an ADR on the NYSE. | Global orthopedic implant and surgery company focused on knee and hip reconstruction, spine surgery, and dental implants. Zimmer Biomet's ROSA robotic surgery platform competes with Stryker's Mako. |
| Investor focus | Orthopedic procedure volume recovery, CORI robotic surgery system adoption, wound management innovation, and operational margin improvement. | ROSA robot adoption, orthopedic procedure volume, international revenue growth, and margin improvement after operational restructuring. |
SNN strengths
- →Diversified across three segments — orthopedics, sports medicine, and wound management — providing revenue resilience
- →CORI robotic surgery system competes in the fast-growing robot-assisted orthopedic surgery market
- →Advanced wound management is a differentiated, high-margin segment with recurring consumable revenue
ZBH strengths
- →ROSA robotic surgery platform is gaining share in the robot-assisted knee replacement market
- →Strong brand presence in knee and hip reconstruction in the US and Europe
- →Dental segment diversification provides revenue outside core orthopedics
Risks to watch — SNN
- →Smith & Nephew has lagged peers in orthopedic revenue growth and has undergone multiple management changes
- →CORI adoption is behind Stryker's Mako and J&J's Velys in installed base
- →UK-listed company with ADR means currency fluctuations affect USD-reported results
Risks to watch — ZBH
- →Zimmer Biomet has lagged Stryker's Mako in robotic surgery market share — a critical competitive battle
- →Restructuring costs and operational complexity have weighed on margins
- →Spine segment faces commoditization pressure from multiple competitors
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →